TScan Therapeutics, Inc. (TCRX)
NASDAQ: TCRX · Real-Time Price · USD
0.1451
0.00 (0.00%)
Nov 17, 2026, 9:53 AM EST - Market open
TScan Therapeutics Employees
TScan Therapeutics had 138 employees as of June 30, 2026. The number of employees decreased by 72 or 34.29% compared to the same quarter last year. That makes TScan Therapeutics the 29,436th largest employer in the world and 3,721st in the United States.
Employees
138
Change (1Y)
-72
Growth (1Y)
-34.29%
Revenue / Employee
$37,580
Profits / Employee
-$833,964
Market Cap
9.83M
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Jun 30, 2026 | 138 | -72 | -34.29% | 138 | 0 |
| Mar 31, 2026 | 139 | -62 | -30.85% | 138 | 1 |
| Dec 31, 2025 | 142 | -53 | -27.18% | 142 | 0 |
| Sep 30, 2025 | 148 | -51 | -25.63% | 146 | 2 |
| Jun 30, 2025 | 210 | 22 | 11.70% | 208 | 2 |
| Mar 31, 2025 | 201 | 34 | 20.36% | 200 | 1 |
| Dec 31, 2024 | 195 | 41 | 26.62% | 194 | 1 |
| Sep 30, 2024 | 199 | 44 | 28.39% | 188 | 11 |
| Jun 30, 2024 | 188 | 39 | 26.17% | 175 | 13 |
| Mar 31, 2024 | 167 | 29 | 21.01% | 161 | 6 |
| Dec 31, 2023 | 154 | 16 | 11.59% | 154 | 0 |
| Sep 30, 2023 | 155 | 24 | 18.32% | 145 | 10 |
| Jun 30, 2023 | 149 | 31 | 26.27% | 135 | 14 |
| Mar 31, 2023 | 138 | 33 | 31.43% | 136 | 2 |
| Dec 31, 2022 | 138 | 33 | 31.43% | 137 | 1 |
| Sep 30, 2022 | 131 | 36 | 37.89% | 127 | 4 |
| Jun 30, 2022 | 118 | 43 | 57.33% | 115 | 3 |
| Mar 31, 2022 | 105 | 44 | 72.13% | 104 | 1 |
| Dec 31, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Aligos Therapeutics | 82 |
| CytoMed Therapeutics | 42 |
| Palatin Technologies | 25 |
| Bolt Biotherapeutics | 23 |
| Lisata Therapeutics | 21 |
| IN8bio | 20 |
| Cellectar Biosciences | 11 |
| Purple Biotech | 10 |
TCRX News
- Just now - TScan Therapeutics Earnings release: Q3 2026 - Filings
- Just now - TScan Therapeutics Quarterly report: Q3 2026 - Filings
- 5 days ago - TScan Therapeutics Reports Third Quarter 2026 Financial Results and Provides Corporate Update - GlobeNewsWire
- 22 days ago - TScan Therapeutics Proxy statement: Proxy filing - Filings
- 4 weeks ago - TScan Therapeutics Proxy statement: Proxy filing - Filings
- 2 months ago - TScan Therapeutics downgraded to Neutral from Buy at H.C. Wainwright - TheFly
- 2 months ago - TScan downgraded to Market Perform from Outperform at LifeSci Capital - TheFly
- 2 months ago - Needham downgrades TScan Therapeutics as company reprioritizes - TheFly